Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set
- PMID: 21880848
- PMCID: PMC3173029
- DOI: 10.3945/ajcn.111.015032
Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set
Abstract
Background: Frequent use of personal, nonprotocol calcium supplements obscured an adverse effect of coadministered calcium and vitamin D (CaD) on cardiovascular risk in the Women's Health Initiative (WHI).
Objective: We investigated the effects of the use of personal calcium or vitamin D supplements on other outcomes in the WHI CaD Study (WHI CaD) by using the WHI limited-access clinical trials data set.
Design: The WHI CaD was a 7-y, randomized, placebo-controlled trial of CaD (1 g Ca/400 IU vitamin D daily) in 36,282 community-dwelling, postmenopausal women. The incidence of total cancer (excluding nonmelanoma skin cancers), breast and colorectal cancers, hip and total fracture, and mortality was assessed by using Cox proportional hazards models.
Results: In the WHI CaD, interactions between the use of either personal calcium or vitamin D supplements and CaD were found for total, breast, and colorectal cancers but not for fracture or mortality. In 15,646 women (43%) who were not taking personal calcium or vitamin D supplements at randomization, CaD significantly decreased the risk of total, breast, and invasive breast cancers by 14-20% and nonsignificantly reduced the risk of colorectal cancer by 17%. In women taking personal calcium or vitamin D supplements, CaD did not alter cancer risk (HR: 1.06-1.26).
Conclusions: For women in the WHI CaD who were not taking personal calcium or vitamin D supplements at randomization, CaD decreased the risk of total, breast, and colorectal cancers and did not change the risk of fractures or total mortality. The nonskeletal effects of CaD may be more important than the skeletal effects and should be considered when evaluating these supplements. The WHI CaD trial is registered at clinicaltrials.gov as NCT00000611.
Figures
Comment in
-
Caution in reinterpreting the Women's Health Initiative (WHI) Calcium and Vitamin D Trial breast cancer results.Am J Clin Nutr. 2012 Jan;95(1):258-9; author reply 259. doi: 10.3945/ajcn.111.027664. Am J Clin Nutr. 2012. PMID: 22189262 No abstract available.
Similar articles
-
The Women's Health Initiative Randomized Trials and Clinical Practice: A Review.JAMA. 2024 May 28;331(20):1748-1760. doi: 10.1001/jama.2024.6542. JAMA. 2024. PMID: 38691368 Review.
-
Long-Term Effect of Randomization to Calcium and Vitamin D Supplementation on Health in Older Women : Postintervention Follow-up of a Randomized Clinical Trial.Ann Intern Med. 2024 Apr;177(4):428-438. doi: 10.7326/M23-2598. Epub 2024 Mar 12. Ann Intern Med. 2024. PMID: 38467003 Clinical Trial.
-
Concordance of Results from Randomized and Observational Analyses within the Same Study: A Re-Analysis of the Women's Health Initiative Limited-Access Dataset.PLoS One. 2015 Oct 6;10(10):e0139975. doi: 10.1371/journal.pone.0139975. eCollection 2015. PLoS One. 2015. PMID: 26440516 Free PMC article. Clinical Trial.
-
Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study.Osteoporos Int. 2013 Feb;24(2):567-80. doi: 10.1007/s00198-012-2224-2. Epub 2012 Dec 4. Osteoporos Int. 2013. PMID: 23208074 Free PMC article. Clinical Trial.
-
Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis.BMJ. 2011 Apr 19;342:d2040. doi: 10.1136/bmj.d2040. BMJ. 2011. PMID: 21505219 Free PMC article. Review.
Cited by
-
Dietary quality index and the risk of breast cancer: a case-control study.BMC Womens Health. 2023 Sep 1;23(1):469. doi: 10.1186/s12905-023-02588-6. BMC Womens Health. 2023. PMID: 37658410 Free PMC article.
-
Vitamin D and Calcium Supplement Use and High-Risk Breast Cancer: A Case-Control Study among BRCA1 and BRCA2 Mutation Carriers.Cancers (Basel). 2023 May 17;15(10):2790. doi: 10.3390/cancers15102790. Cancers (Basel). 2023. PMID: 37345127 Free PMC article.
-
Vitamin D intake and all-cause and cause-specific mortality in Japanese men and women: the Japan Public Health Center-based prospective study.Eur J Epidemiol. 2023 Mar;38(3):291-300. doi: 10.1007/s10654-023-00968-8. Epub 2023 Jan 31. Eur J Epidemiol. 2023. PMID: 36719520 Free PMC article.
-
Serum 25-Hydroxyvitamin D and Cancer Risk: A Systematic Review of Mendelian Randomization Studies.Nutrients. 2023 Jan 13;15(2):422. doi: 10.3390/nu15020422. Nutrients. 2023. PMID: 36678292 Free PMC article. Review.
-
Circulating vitamin D and breast cancer risk: an international pooling project of 17 cohorts.Eur J Epidemiol. 2023 Jan;38(1):11-29. doi: 10.1007/s10654-022-00921-1. Epub 2023 Jan 3. Eur J Epidemiol. 2023. PMID: 36593337 Free PMC article.
References
-
- Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, Sandler RS, Rothstein R, Summers RW, Snover DC, Beck GJ, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999;340:101–7 - PubMed
-
- Bonithon-Kopp C, Kronborg O, Giacosa A, Rath U, Faivre J. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet 2000;356:1300–6 - PubMed
-
- Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007;85:1586–91 - PubMed
-
- Autier P, Gandini S, Vitamin D. Supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007;167:1730–7 - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous